Search Page

1

Cite

Share

Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites.

Hall DB, Macgregor TR. Hall DB, et al. HIV Clin Trials. 2007 Nov-Dec;8(6):391-9. doi: 10.1310/hct0806-391. HIV Clin Trials. 2007. PMID: 18042504

Cite

Share

2

Cite

Share

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.

Yuan J, Guo S, Hall D, Cammett AM, Jayadev S, Distel M, Storfer S, Huang Z, Mootsikapun P, Ruxrungtham K, Podzamczer D, Haas DW; Nevirapine Toxicogenomics Study Team. Yuan J, et al. AIDS. 2011 Jun 19;25(10):1271-80. doi: 10.1097/QAD.0b013e32834779df. AIDS. 2011. PMID: 21505298 Free PMC article.

Cite

Share

3

Cite

Share

Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine.

Lehr T, Yuan J, Hall D, Zimdahl-Gelling H, Schaefer HG, Staab A, MacGregor TR, Jayadev S. Lehr T, et al. Pharmacogenet Genomics. 2011 Nov;21(11):721-30. doi: 10.1097/FPC.0b013e32834a522e. Pharmacogenet Genomics. 2011. PMID: 21860339 Clinical Trial.

Cite

Share

4

Cite

Share

Induction-maintenance antiretroviral therapy: proof of concept.

Hall DB, Montaner JG, Reiss P, Cooper D, Vella S, Dohnanyi C, Myers M, Lange J, Conway B. Hall DB, et al. AIDS. 1998 May 7;12(7):F41-4. doi: 10.1097/00002030-199807000-00001. AIDS. 1998. PMID: 9619796

Cite

Share

5

Cite

Share

A group sequential adaptive treatment assignment design for proof of concept and dose selection in headache trials.

Hall DB, Meier U, Diener HC. Hall DB, et al. Contemp Clin Trials. 2005 Jun;26(3):349-64. doi: 10.1016/j.cct.2005.02.001. Epub 2005 Mar 28. Contemp Clin Trials. 2005. PMID: 15911469

Cite

Share

6

Cite

Share

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.

Mayers DL, Chung J, Kohlbrenner VM, Hall DB, DeMasi RA, Neubacher D, Buss NE, Salgo MP. Mayers DL, et al. Among authors: hall db. AIDS Res Hum Retroviruses. 2006 Nov;22(11):1110-2. doi: 10.1089/aid.2006.22.1110. AIDS Res Hum Retroviruses. 2006. PMID: 17147497 No abstract available.

Cite

Share

7

Cite

Share

Short communication: Phenotypic protease inhibitor resistance and cross-resistance in the clinic from 2006 to 2008 and mutational prevalences in HIV from patients with discordant tipranavir and darunavir susceptibility phenotypes.

Bethell R, Scherer J, Witvrouw M, Paquet A, Coakley E, Hall D. Bethell R, et al. AIDS Res Hum Retroviruses. 2012 Sep;28(9):1019-24. doi: 10.1089/AID.2011.0242. Epub 2012 Mar 23. AIDS Res Hum Retroviruses. 2012. PMID: 22098079

Cite

Share

8

Cite

Share

Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.

Krueger JG, Ferris LK, Menter A, Wagner F, White A, Visvanathan S, Lalovic B, Aslanyan S, Wang EE, Hall D, Solinger A, Padula S, Scholl P. Krueger JG, et al. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. doi: 10.1016/j.jaci.2015.01.018. Epub 2015 Mar 11. J Allergy Clin Immunol. 2015. PMID: 25769911 Clinical Trial.

Cite

Share

9

Cite

Share

Confidence intervals and controlled clinical trials: incompatible tools for medical research.

Hall DB. Hall DB. J Biopharm Stat. 1993 Sep;3(2):257-63. doi: 10.1080/10543409308835064. J Biopharm Stat. 1993. PMID: 8220408

Cite

Share

10

Cite

Share

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. Feagan BG, et al. Among authors: hall db. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25. Lancet Gastroenterol Hepatol. 2018. PMID: 30056030 Free article. Clinical Trial.

Cite

Share